ONCC Chemotherapy Immunotherapy Certificate
Exam
3 major phases of cell division: - ANS-Interphase
Mitotic phase
Cytokinesis
3 steps of interphase: - ANS-First growth phase (G1)
Synthesis phase (S phase)
Second growth phase (G2)
4 phases of mitosis: - ANS-Prophase
Metaphase
Anaphase
Telophase
Innate immunity: - ANS-Non-specific response, either:
1. Barrier (skin, mucous membranes, flora of skin/gut)
2. Cellular components (phagocytes, natural killer cells, granulocytes, macrophages)
Adaptive immunity: - ANS-Follows innate immunity if unsuccessful. Memory immunity,
including:
1. Humoral immunity (production of antibodies or immunoglobulins)
2. Cell mediated immunity (dependent upon T cells)
3. Regulatory T -cells (prevent autoimmune reactions and limit inflammatory responses)
Define mutations - ANS-Variations in the nucleotide sequence of a gene
3 main goals of treatment: - ANS-Cure
Control
Palliation
Define neoadjuvant therapy - ANS-Treatment is given prior to surgery to shrink the
tumor
Define adjuvant therapy - ANS-Additional cancer treatment given after the primary
treatment to lower the risk that the cancer reoccur
Define conditioning/preparative therapy - ANS-Treatments used to prepare a patient for
stem cell transplantation
2 types of conditioning therapies: - ANS-Myeloablative
Nonmyeloablative
Define dose density - ANS-Drug dose per unit of time
, Define dose intensity - ANS-Amount of drug delivered over time
How is relative dose intensity (RDI) calculated? - ANS-By comparing the dose that the
patient ACTUALLY received to the planned dose of the standard regimen
How do alkylating agents work? - ANS-By causing a break in the DNA helix strand,
interfering with DNA replication and causing cell death
3 subcategories of alkylating agents: - ANS-1. Nitrogen mustards
2. Platinum-based agents (do not possess an alkyl group but still termed alkylating
agents as they work similarly)
3. Nitrosoureas
Most common subcategory of alkylating agents: - ANS-Nitrogen mustards
Common alkylating agents: - ANS-Cyclophosphamide (Cytoxan)
Ifosfamide (Ifex)
Bendamustine (Treanda)
Common platinum-based agents: - ANS-Cisplatin (Platinol)
Carboplatin (Paraplatin)
What is unique about nitrosoureas agents? - ANS-Able to cross the blood-brain barrier;
can be effective in treating some brain tumors
Common nitrosoureas agents: - ANS-Carmustine (BiCNU)
Lomustine (CeeNu)
Streptozocin (Zanosar)
Hypersensitivity can occur with late doses of: - ANS-Carboplatin
These agents are typically categorized as highly emetogenic: - ANS-1. Alkylating agents
2. Nitrosoureas
Pre-administration labs for alkylating agents and nitrosoureas: - ANS-BUN
Creatinine
CBC w/ diff
What is the medication Mesna used for? - ANS-Bladder protectant with administration of
cyclophosphamide or ifosfamide
Instruct pts receiving ________ to avoid exposure to cold air and consuming cold fluids
for 3-4 days following treatment - ANS-Oxaliplatin
Exam
3 major phases of cell division: - ANS-Interphase
Mitotic phase
Cytokinesis
3 steps of interphase: - ANS-First growth phase (G1)
Synthesis phase (S phase)
Second growth phase (G2)
4 phases of mitosis: - ANS-Prophase
Metaphase
Anaphase
Telophase
Innate immunity: - ANS-Non-specific response, either:
1. Barrier (skin, mucous membranes, flora of skin/gut)
2. Cellular components (phagocytes, natural killer cells, granulocytes, macrophages)
Adaptive immunity: - ANS-Follows innate immunity if unsuccessful. Memory immunity,
including:
1. Humoral immunity (production of antibodies or immunoglobulins)
2. Cell mediated immunity (dependent upon T cells)
3. Regulatory T -cells (prevent autoimmune reactions and limit inflammatory responses)
Define mutations - ANS-Variations in the nucleotide sequence of a gene
3 main goals of treatment: - ANS-Cure
Control
Palliation
Define neoadjuvant therapy - ANS-Treatment is given prior to surgery to shrink the
tumor
Define adjuvant therapy - ANS-Additional cancer treatment given after the primary
treatment to lower the risk that the cancer reoccur
Define conditioning/preparative therapy - ANS-Treatments used to prepare a patient for
stem cell transplantation
2 types of conditioning therapies: - ANS-Myeloablative
Nonmyeloablative
Define dose density - ANS-Drug dose per unit of time
, Define dose intensity - ANS-Amount of drug delivered over time
How is relative dose intensity (RDI) calculated? - ANS-By comparing the dose that the
patient ACTUALLY received to the planned dose of the standard regimen
How do alkylating agents work? - ANS-By causing a break in the DNA helix strand,
interfering with DNA replication and causing cell death
3 subcategories of alkylating agents: - ANS-1. Nitrogen mustards
2. Platinum-based agents (do not possess an alkyl group but still termed alkylating
agents as they work similarly)
3. Nitrosoureas
Most common subcategory of alkylating agents: - ANS-Nitrogen mustards
Common alkylating agents: - ANS-Cyclophosphamide (Cytoxan)
Ifosfamide (Ifex)
Bendamustine (Treanda)
Common platinum-based agents: - ANS-Cisplatin (Platinol)
Carboplatin (Paraplatin)
What is unique about nitrosoureas agents? - ANS-Able to cross the blood-brain barrier;
can be effective in treating some brain tumors
Common nitrosoureas agents: - ANS-Carmustine (BiCNU)
Lomustine (CeeNu)
Streptozocin (Zanosar)
Hypersensitivity can occur with late doses of: - ANS-Carboplatin
These agents are typically categorized as highly emetogenic: - ANS-1. Alkylating agents
2. Nitrosoureas
Pre-administration labs for alkylating agents and nitrosoureas: - ANS-BUN
Creatinine
CBC w/ diff
What is the medication Mesna used for? - ANS-Bladder protectant with administration of
cyclophosphamide or ifosfamide
Instruct pts receiving ________ to avoid exposure to cold air and consuming cold fluids
for 3-4 days following treatment - ANS-Oxaliplatin
